143 related articles for article (PubMed ID: 9621296)
1. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.
Julian BA; Brantley RR; Barker CV; Stopka T; Gaston RS; Curtis JJ; Lee JY; Prchal JT
J Am Soc Nephrol; 1998 Jun; 9(6):1104-8. PubMed ID: 9621296
[TBL] [Abstract][Full Text] [Related]
2. Blockade of angiotensin II AT 1 receptor reduces hematocrit in patients with posttransplant erythrocytosis.
Tsang WK; Tong KL; Chan HW
Transplant Proc; 1998 Nov; 30(7):3072-3. PubMed ID: 9838354
[No Abstract] [Full Text] [Related]
3. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis.
Hortal L; Fernández A; Vega N; Rodríguez JC; Losada A; Lorenzo M; Plaza C; Palop L
Transplant Proc; 1998 Aug; 30(5):2127-8. PubMed ID: 9723415
[No Abstract] [Full Text] [Related]
4. Effects of losartan on the treatment of posttransplant erythrocytosis.
Navarro JF; García J; Macía M; Mora C; Chahin J; Gallego E; Méndez ML; del Castillo N
Clin Nephrol; 1998 Jun; 49(6):370-2. PubMed ID: 9696433
[TBL] [Abstract][Full Text] [Related]
5. New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients.
Sauron C; Berthoux P; Berthoux F; Alamartine E; Diab N; Broyet C; Hacini J
Transplant Proc; 1993 Feb; 25(1 Pt 2):1032-3. PubMed ID: 8382847
[No Abstract] [Full Text] [Related]
6. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis.
Klaassen RJ; van Gelder T; Rischen-Vos J; Deinum J; Man in't Veld AJ; Weimar W
Transplantation; 1997 Sep; 64(5):780-2. PubMed ID: 9311722
[TBL] [Abstract][Full Text] [Related]
7. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
Wang AY; Yu AW; Lam CW; Yu LM; Li PK; Goh J; Lui SF
Am J Kidney Dis; 2002 Mar; 39(3):600-8. PubMed ID: 11877580
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].
Morale W; Puliatti C; Veroux P; Veroux M; Valvo C; Cappello D; Puliatti D; Francesco L
Minerva Urol Nefrol; 2002 Jun; 54(2):145-8. PubMed ID: 12070465
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers.
Vishnu P; Moreno Vanegas Y; Wadei HM; Rivera CE
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29954763
[TBL] [Abstract][Full Text] [Related]
10. Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis.
Iñigo P; Torregrosa JV; Campistol JM; Oppenheimer F
Transplant Proc; 1999 Sep; 31(6):2321. PubMed ID: 10500598
[No Abstract] [Full Text] [Related]
11. Successful long-term treatment of post-transplant erythrocytosis with losartan.
Midtvedt K; Stokke ES; Hartmann A
Nephrol Dial Transplant; 1996 Dec; 11(12):2495-7. PubMed ID: 9017632
[No Abstract] [Full Text] [Related]
12. The effect of losartan on posttransplant erythrocytosis.
Colak T; Emiroglu R; Karakayali H; Haberal M
Transplant Proc; 2001; 33(1-2):2014-5. PubMed ID: 11267606
[No Abstract] [Full Text] [Related]
13. Use of aminophylline and enalapril in posttransplant polycythemia.
Mazzali M; Filho GA
Transplantation; 1998 Jun; 65(11):1461-4. PubMed ID: 9645803
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors reduce hemoglobin concentrations, hematocrit, and serum erythropoietin levels in renal transplant recipients without posttransplant erythrocytosis.
Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Risaliti A; Baccarani U; Mioni G
Transplant Proc; 2001; 33(1-2):2038-40. PubMed ID: 11267615
[No Abstract] [Full Text] [Related]
15. Expression of angiotensin II type I receptor on erythroid progenitors of patients with post transplant erythrocytosis.
Gupta M; Miller BA; Ahsan N; Ulsh PJ; Zhang MY; Cheung JY; Yang HC
Transplantation; 2000 Oct; 70(8):1188-94. PubMed ID: 11063339
[TBL] [Abstract][Full Text] [Related]
16. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients.
Klingbeil AU; Müller HJ; Delles C; Fleischmann E; Schmieder RE
Am J Hypertens; 2000 Dec; 13(12):1295-300. PubMed ID: 11130774
[TBL] [Abstract][Full Text] [Related]
17. Benefit of angiotensin II receptor blockade in the treatment of posttransplant polycythemia in renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Abouljoud M; Escobar F; Mozes M
Transplant Proc; 1997; 29(1-2):207-8. PubMed ID: 9122965
[No Abstract] [Full Text] [Related]
18. Posttransplant erythrocytosis: a possible nonerythropoietin-mediated mechanism.
Morrone LF; Schena A; Di Paolo S; Stallone G; Schena FP
Transplant Proc; 1997; 29(1-2):223. PubMed ID: 9122971
[No Abstract] [Full Text] [Related]
19. Correction of posttransplant erythrocytosis with enalapril.
Rell K; Koziak K; Jarzyo I; Lao M; Gaciong Z
Transplantation; 1994 Apr; 57(7):1059-63. PubMed ID: 8165703
[TBL] [Abstract][Full Text] [Related]
20. A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation.
Beckingham IJ; Woodrow G; Hinwood M; Rigg KM; Morgan AG; Burden RP; Broughton-Pipkin F
Nephrol Dial Transplant; 1995 Dec; 10(12):2316-20. PubMed ID: 8808232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
